The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis
Critical Care2011Vol. 15(5), pp. R261–R261
Citations Over TimeTop 10% of 2011 papers
Philipp Kümpers, Faikah Gueler, Sascha David, Paul Van Slyke, Daniel Dumont, Joon-Keun Park, Clemens L. Bockmeyer, Samir M. Parikh, Hermann Pavenstädt, Hermann Haller, Nelli Shushakova
Abstract
We provide proof of principle in support of the efficacious use of PEGylated VT, a drug-like Tie2 receptor agonist, to counteract microvascular endothelial barrier dysfunction and reduce mortality in a clinically relevant murine sepsis model. Further studies are needed to pave the road for clinical application of this therapeutic concept.
Related Papers
- → Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1(2002)1,010 cited
- → The role of the Angiopoietins in vascular morphogenesis(2009)393 cited
- → Angiopoietin-2/Tie2 signaling involved in TNF-a induced peritoneal angiogenesis(2012)10 cited
- → Angiopoietin-2/Tie2 Signaling Involved in TNF-α Induced Peritoneal Angiogenesis(2012)10 cited
- Role of angiopoietin-tie2 system in ocular vascular diseases = 안구 혈관 질환에서 Angiopoietin-Tie2 신호전달체계의 역할(2018)